Developing non-invasive molecular markers for early risk assessment of Alzheimer's disease
Alzheimer's disease (AD) is a heterogeneous neurodegenerative disease, with no standard biomarker(s) to detect or confirm its risk at an early stage. The prevalence of AD increases exponentially worldwide in people of ages over 65 and older. Current improvements have unveiled the disease's...
Saved in:
Main Authors: | Tapas K. Sur, Tanmoy Mondal, Zarish Noreen, Jheannelle Johnson, Gail Nunlee-Bland, Christopher A. Loffredo, Brent E. Korba, Vijay Chandra, Siddhartha S. Jana, Bernard Kwabi-Addo, Sumit Sarkar, Somiranjan Ghosh |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-06-01
|
Series: | Biomarkers in Neuropsychiatry |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666144625000024 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Natural bioactive compounds form herbal medicine in Alzheimer’s disease: from the perspective of GSK-3β
by: Mei Wang, et al.
Published: (2025-02-01) -
Neuroprotective role of epigallocatechin-3-gallate, albeginin and melanoxetin in alzheimer's disease
by: Arif Malik, et al.
Published: (2025-02-01) -
C/EBPβ in Alzheimer’s disease: An integrative regulator of pathological mechanisms
by: Xiaoting Luo, et al.
Published: (2025-02-01) -
Prion meeting 2023: implications of a growing field
by: Tiago F. Outeiro, et al.
Published: (2024-12-01) -
Therapeutic effect of dihydroartemisinin on Alzheimer’s disease model mice with senile macular degeneration
by: Gao Han, et al.
Published: (2025-02-01)